Receive The Newest Study Notifications

ExCellThera Inc., a clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that its lead technology, ECT-001, will be used as part of two new clinical trials in...

Expands global footprint for lead immuno-oncology program, BXCL701 Patient recruitment in US tNEPC study on-track; additional sites being activated Immuno-oncology Clinical Advisory Board expanded with addition of prominent U.K. medical oncologist, Professor Johann de...

Brisbane, Calif.-based Aimmune Therapeutics announced that its Phase III European clinical trial of AR101 for treatment of peanut allergy met its primary efficacy endpoint. In November 2018, the company had announced the publication of its successful Phase III...

Stem Cell Global Boom The widespread global outreach potential of stem cell therapies is becoming apparent, especially given the recent news of a second person going into long-term remission (some saying “cured”) of HIV after undergoing a stem cell transplant....

A Chinese vaccine against the Hepatitis E virus (HEV) has been approved by the U.S. Food and Drug Administration (FDA) to enter clinical trials in April. The vaccine, sold under the trade name Hecolin, was initially developed by a research team from Xiamen University...

Use of IBM Watson for Clinical Trial Matching Expands Health Quest’s Use of AI “Health Quest is committed to becoming a leader in the application of AI and other advanced technology to improve patient care and provider performance. Watson for Clinical Trial Matching...

New Survey Finds That Although Understanding of Alzheimer's Disease is Limited to Personal Experience, Respondents Were Interested in Actively Taking Part in Early Detection and Clinical Trials Today, the Alliance for Aging Research (the "Alliance") released new...

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced that it has been granted approval by the Alfred Hospital Ethics Committee to perform a Phase I clinical trial for Metablok, the Company’s lead drug candidate for...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that the first two patients have been enrolled in its European...

Lead investigator Prof. Salman Siddiqui sees potential to provide an alternative to oral steroids or biologic injections for severe asthma patients with high eosinophil counts Knopp Biosciences LLC, a privately held drug discovery and development company focused on...

Dr. Neil Singla, Chief Executive Officer of Lotus Clinical Research, will chair the 4th annual American Pain Society Conference on Analgesic Trials on Wednesday, April 3, 2019 in Milwaukee, Wisconsin. The theme of this year's APS-CAT is Accelerating Development of...

 Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces it has commenced clinical studies for the Company’s lead asset NXP001. NXP001 is in development as a...

DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a proof-of-concept trial with topical DUR-928 in patients with mild to moderate plaque psoriasis.  DUR-928, the lead investigational product in the Company's Epigenetic...

Use of IBM Watson for Clinical Trial Matching Expands Health Quest's Use of AI Health Quest Systems Inc., a four-hospital health system operating in New York's Hudson Valley and northwest Connecticut, and IBM Watson Health (NYSE: IBM) have entered an agreement that...

There is a well-known saying in the Pharmaceutical industry when confronted about the approach to executing and managing clinical trials. It is also the most expensive saying in business: "We have always done it that way". The FDA has recently reaffirmed its...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer's disease has been initiated. BAN2401 is...

Spencer Hoover, vice president and executive director of the Henry Ford Cancer Institute, is co-author of a manuscript published in the Journal of Oncology Practice aimed at establishing best practices to promote diversity in clinical trials. In-depth interviews were...

Data to be published in the Journal of the National Comprehensive Cancer Network Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced top-line results from the company’s Phase 2b ENCORE-NF clinical trial in patients with biopsy-confirmed nonalcoholic...

Neurotrope Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today issued a statement on Biogen Inc.'s decision to discontinue its global Phase 3 trials of...

Adlai Nortye Ltd. ("Adlai Nortye"), a global clinical-stage biopharmaceutical company today announced that it has received a clearance from the National Medical Products Administration (NMPA) of China for initiating the open-label, randomized, multicenter, global...